Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421500 | 1.00 | TSHR (0.53) | TSHRALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL17146906 | 0.90 | TSHR (0.59) | TSHRALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL4154910 | 0.81 | ALDH1A1 (0.56) | TSHRALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL13164028 | 0.79 | TSHR (0.44) | TSHRALDH1A1KMT2AHSD17B10CA12 | |
| SCHEMBL14629167 | 0.78 | TSHR (0.52) | TSHRALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL31021826 | 0.78 | MGAM (0.47) | TSHRALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL20201217 | 0.78 | ALDH1A1 (0.57) | TSHRALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL907851 | 0.76 | SIRT3 (0.58) | TSHRALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL12359379 | 0.76 | TSHR (0.48) | TSHRALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL20338287 | 0.76 | TSHR (0.48) | TSHRALDH1A1KMT2AMEN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655295-A1 | SUBSTITUTED 1H-PYRAZOLE-4-CARBOXAMIDES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2024158607-A1 | SUBSTITUTED 1H-PYRAZOLE-4-CARBOXAMIDES AS SARM1 INHIBITORS | DISARM THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024158775-A1 | PYRIDAZINES AS SARM1 INHIBITORS | DISARM THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3746135-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | TSHR 2748/4885ALDH1A1 2806/4885KMT2A 1210/4885 |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | BMI1, EZH2, SUZ12 | TSHR 4567/4885ALDH1A1 1225/4885KMT2A 51/4885 |
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | TSHR 4655/4885ALDH1A1 2034/4885KMT2A 583/4885 |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | TSHR 4655/4885ALDH1A1 2034/4885KMT2A 583/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | TSHR 4655/4885ALDH1A1 2034/4885KMT2A 583/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | TSHR 4567/4885ALDH1A1 1225/4885KMT2A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.